Compare XRTX & SHFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XRTX | SHFS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Canada | United States |
| Employees | N/A | 41 |
| Industry | Pharmaceuticals and Biotechnology | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.7M |
| IPO Year | 2018 | N/A |
| Metric | XRTX | SHFS |
|---|---|---|
| Price | $0.38 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 39.3K | ★ 89.8K |
| Earning Date | 05-15-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.72 |
| 52 Week High | $1.41 | $9.18 |
| Indicator | XRTX | SHFS |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 42.87 |
| Support Level | $0.37 | $0.80 |
| Resistance Level | $0.60 | $1.03 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 18.66 | 13.28 |
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.